Demant CEO: Prognosis held back by uncertainty about momentum's duration

Demant’s first-quarter success was partially due to the launch of flagship product Oticon Real, which created particular interest among hearing aid users.
Søren Nielsen, chief executive officer of Demant. | Photo: Kenneth Lysbjerg Koustrup
Søren Nielsen, chief executive officer of Demant. | Photo: Kenneth Lysbjerg Koustrup
by marketwire, translated by christian radich hoffman

Hearing aid manufacturer Demant’s upwards adjustment of its 2023 prognosis in mid-April is mainly steered by the strong development during the year’s first quarter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading